rTMS for Depression

Repetitive Transcranial Magnetic Stimulation for Depression

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06484413

Enrollment

Registered

2024-07-03

Start date

2016-08-23

Completion date

2022-04-19

Last updated

2024-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Brief summary

This is a longitudinal observational study, where we will track outcomes in patients undergoing 5 weeks of FDA approved right DLPFC rTMS treatment.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Inclusion criteria

1. Male or female subjects 18 to 80 years of age 2. DSM V diagnosis of a major depressive episode Subjects must have an initial score of at least 20 on the HAMD at screen 3. rTMS is clinically indicated 4. Patient is competent to provide informed consent

Exclusion criteria

1. Lifetime DSM-V diagnosis of schizophrenia, schizoaffective disorder, psychotic depression or any other psychotic disorder as defined in the DSM-V 2. Current (within the last year) diagnosis of anxiety disorder, obsessive- compulsive disorder, or eating disorder that precedes the onset of the current episode of depression and is the primary diagnosis 3. Current diagnosis of delirium, dementia, or amnestic amnesiac disorder 4. Diagnosis of mental retardation 5. Baseline Mini Mental State Exam (MMSE) score \< 21 or a total score falling two standard deviations below the age- and education-adjusted mean, whichever is less 6. Any active general medical condition or CNS disease which can affect cognition or response to treatment 7. Current (within the past three months) diagnosis of active substance dependence, or active substance abuse within the past week as indicated by self-report. 8. ECT or rTMS within three months 9. Pregnancy as indicated by self-report 10. MRI contraindications 11. Implanted electronic device or metal implant in the head and neck region (DBS, cochlear implant, etc) 12. Change in the dose of psychotropic medications within the past week Inclusion Criteria for healthy volunteers: 1. Male or female between age 18 and 80 2. Patient is competent to provide informed consent

Design outcomes

Primary

Measure	Time frame	Description
MADRS	5 weeks	Montgomery-Asberg Depression Rating Scale

Outcome results